Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome

• Published in: Clinical endocrinology (Oxford) 2017-12, Vol.87 (6), p.767-774
• Main Authors: Liu, Xin, Zhang, Ying, Zheng, Si‐yuan, Lin, Rong, Xie, Yi‐juan, Chen, Hui, Zheng, Yong‐xiong, Liu, En, Chen, Lin, Yan, Jia‐he, Xu, Wei, Mai, Ting‐ting, Gong, Yi
• Format: Article
• Language: English
• Subjects: Adipose tissue; Adolescent; Adult; Body weight; Exenatide; Female; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents - therapeutic use; Inflammation; Insulin; Insulin resistance; Menstrual cycle; Menstrual Cycle - drug effects; Menstruation; Metabolism; Metformin; Obesity; Obesity - drug therapy; Overweight; Overweight - drug therapy; overweight/obese; Peptides - therapeutic use; Polycystic ovary syndrome; Polycystic Ovary Syndrome - drug therapy; Pregnancy; Pregnancy Rate; Prospective Studies; Venoms - therapeutic use; Weight Loss - drug effects; Young Adult
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.13454

Summary Context Weight loss remains one of the most important arms in obese patients with polycystic ovary syndrome (PCOS). Further studies are needed to identify the best treatment. Objective To evaluate the effects of exenatide (EXE) on reproductive and metabolic function in overweight/obese (OW/OB) PCOS. Design This is a 24‐week open‐label prospective, randomized, clinical study. Patients and Measurements This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks. Then all patients were treated with MET alone during the second 12 weeks. We observed metabolic parameters at 0 and 12 weeks, and then tracked the rate of pregnancy during the second 12 weeks. Results After the first 12 weeks of intervention, compared with MET, subjects who received EXE had significantly decreased weight (4.29 ± 1.29 kg vs 2.28 ± 0.55 kg, P